Joint Working Executive Summary

Project Title	The Clatterbridge Cancer Centre NHS Foundation Trust (CCC)
	Renal Cell Carcinoma (RCC) Service Development Project
Project Partners	Ipsen Ltd The Clatterbridge Cancer Centre NHS Foundation Trust
Joint Working Project Summary	This project reflects collaboration between Ipsen, and The Clatterbridge Cancer Centre (CCC) within the remit of a joint working project to support a Renal Cell Carcinoma (RCC) Service development. The project will run for 24 months. The principal aims of this joint working project comprises of redesigning and enhancing the renal care service for outpatients both at CCC and sector hubs: to provide renal specialist clinical care and to optimise the patient pathway. This will result in a more efficient and joined up service.
Expected benefits to patients, the NHS and lpsen	 Anticipated benefits for patients Potential for care closer to home More equitable and consistent access to care Improved quality of care Continuity of care and dedicated advice service therefore improved patient experience and satisfaction Anticipated benefits for NHS Improved quality and consistency of care Improved productivity/better use of resources/free up outpatient capacity Services configured around patients' needs resulting in better health outcomes & clearer and improved care pathways Develop & strengthen links with local hubs through education programme enabling equity of access, improving teamwork and upskilling work force Transforming Cancer Care agenda – project is an exemplar for innovation
	 Anticipated benefits for Ipsen Improved professional relationship and trust between IPSEN and Clatterbridge Cancer Centre Improved reputation: demonstrates Ipsen's commitment to Oncology Patients may receive appropriate Ipsen products if clinically indicated in accordance with local and national clinical guidelines Opportunity to further support service redesign and improve patient pathways Better understanding of customers' and patients' needs
Project start date and duration	May 2021 – 2 years Extended following agreement by both parties to April 2024 due to COVID-19.